Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Atai Life Sciences N.V. (ATAI)

1.81   0.21 (13.13%) 03-31 16:00
Open: 1.73 Pre. Close: 1.6
High: 1.88 Low: 1.7
Volume: 4,327,699 Market Cap: 359(M)

Technical analysis

as of: 2023-03-31 4:16:51 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 2.19     One year: 2.56
Support: Support1: 1.42    Support2: 1.13
Resistance: Resistance1: 1.87    Resistance2: 2.19
Pivot: 1.32
Moving Average: MA(5): 1.53     MA(20): 1.35
MA(100): 2.18     MA(250): 3.21
MACD: MACD(12,26): -0.1     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 88.8     %D(3): 76.6
RSI: RSI(14): 67.3
52-week: High: 5.44  Low: 1.13
Average Vol(K): 3-Month: 1,500 (K)  10-Days: 1,707 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ATAI ] has closed Bollinger Bands are 4.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.7 - 1.71 1.71 - 1.71
Low: 1.54 - 1.54 1.54 - 1.55
Close: 1.59 - 1.6 1.6 - 1.61

Company Description

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Headline News

Sat, 01 Apr 2023
TDR's Top 5 Psychedelic Developments For The Week Of March 27 - The Dales Report

Fri, 31 Mar 2023
Should Biotechnology Stock ATAI Life Sciences NV (ATAI) Be in Your Portfolio Friday? - InvestorsObserver

Thu, 30 Mar 2023
Apeiron Founder Christian Angermayer Makes Follow-On Purchase ... - The Dales Report

Thu, 30 Mar 2023
$1.6M Bet On ATAI Life Sciences? Check Out These 4 Penny Stocks ... - Benzinga

Wed, 29 Mar 2023
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are ... - Benzinga

Thu, 23 Mar 2023
Is ATAI Life Sciences NV (ATAI) Stock a Good Value Thursday? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 166 (M)
% Held by Insiders 1.3676e+008 (%)
% Held by Institutions 9.2 (%)
Shares Short 4,500 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.4535e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -34
Return on Assets (ttm) 233.8
Return on Equity (ttm) -22
Qtrly Rev. Growth 425000
Gross Profit (p.s.) 0.12
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -94 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 4.07e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.